Foghorn Therapeutics (FHTX) Accounts Payables (2019 - 2026)

Foghorn Therapeutics' Accounts Payables history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 70.16% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 70.16% YoY), while the FY2025 annual figure was $4.3 million, up 12.71% from the prior year.
• Accounts Payables was $6.9 million for Q1 2026 at Foghorn Therapeutics, up from $4.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.8 million in Q3 2023 to a low of $3.2 million in Q3 2025.
• Historically, Accounts Payables has averaged $5.8 million across 5 years, with a median of $5.4 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 137.7% in 2022, then plunged 60.78% in 2024.
• A 5-year view of Accounts Payables shows it stood at $5.4 million in 2022, then gained by 15.63% to $6.3 million in 2023, then tumbled by 39.54% to $3.8 million in 2024, then grew by 12.71% to $4.3 million in 2025, then jumped by 62.31% to $6.9 million in 2026.
• The last three Accounts Payables figures came in at $6.9 million (Q1 2026), $4.3 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.